Intended for healthcare professionals


Sixty seconds on . . . solanezumab

BMJ 2016; 355 doi: (Published 29 November 2016) Cite this as: BMJ 2016;355:i6389
  1. Nigel Hawkes
  1. London

More bad news on drugs for Alzheimer’s disease?

Yes, another drug has failed in phase III trials. This one is solanezumab, whose demise was a three act drama that’s finally seen the curtain fall.1 2 3

Was that a surprise?

Not really. Alzheimer’s disease is the graveyard of drug discovery. One study found that of 244 compounds tested between 2000 and 2014 only one was ever licensed, a failure rate of 99.6%.4

That implies everybody’s doing something wrong

Or …

View Full Text

Log in

Log in through your institution


* For online subscription